# FY4/23 1Q IR PRESENTATION 

AIN HOLDINGS INC.

September 2022

Results Overview

## Consolidated P/L

Net sales increased $8.6 \%$ YoY and declined $0.5 \%$ against the plan despite the impact of the COVID-19. Ordinary profit increased $7.9 \%$ YoY and declined $2.9 \%$ against the plan due to increase of sales.

| ( $\ddagger$ million) | $\begin{gathered} \mathrm{FY} 4 / 221 \mathrm{Q} \\ \text { results } \end{gathered}$ | $\underset{\text { plan }}{\mathrm{FY} 4 / 23} 1 \mathrm{Q}$ | $\begin{gathered} \mathrm{FY} 4 / 231 \mathrm{Q} \\ \text { results } \end{gathered}$ | YoY change | $\begin{gathered} \text { YoY } \\ \text { change(\%) } \end{gathered}$ | Vs plan (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 75,011 | 81,887 | 81,470 | +6,459 | +8.6 | (0.5) |
| Gross profit | 11,060 | 12,471 | 11,643 | +583 | +5.3 | (6.6) |
| \% of net sales | 14.7 | 15.2 | 14.3 |  |  |  |
| SG\&A expenses | 8,448 | 9,413 | 8,890 | +442 | +5.2 | (5.6) |
| \% of net sales | 11.3 | 11.5 | 10.9 |  |  |  |
| Operating profit | 2,611 | 3,058 | 2,753 | +142 | +5.4 | (10.0) |
| \% of net sales | 3.5 | 3.7 | 3.4 |  |  |  |
| Ordinary profit | 2,864 | 3,180 | 3,089 | +225 | +7.9 | (2.9) |
| \% of net sales | 3.8 | 3.9 | 3.8 |  |  |  |
| Profit attributable to owners of parent | 1,309 | 1,450 | 1,704 | +395 | +30.2 | +17.5 |
| \% of net sales | 1.7 | 1.8 | 2.1 |  |  |  |
| Earnings per share ( $¥$ ) | 37.10 | 41.19 | 48.53 | +11.43 | +30.8 | +17.8 |

Figures in the table are rounded down

## Dispensing Pharmacy Business (Consolidated)

Net sales increased $8.5 \%$ YoY and declined $0.5 \%$ against the plan due to new store openings including M\&A and contribution of stores opened previous year. Segment profit declined 3.0\% YoY and $12.2 \%$ against the plan.

| ( $\ddagger$ million) | $\begin{gathered} \text { FY4/22 1Q } \\ \text { results } \end{gathered}$ | $\underset{\text { plan }}{\mathrm{FY} 4 / 231 Q}$ | $\begin{gathered} \text { FY4/23 1Q } \\ \text { results } \end{gathered}$ | Yoy change | $\begin{gathered} \text { YoY } \\ \text { change(\%) } \end{gathered}$ | Vs plan (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 66,828 | 72,810 | 72,482 | +5,654 | +8.5 | (0.5) |
| Gross profit | 8,138 | 9,150 | 8,327 | +189 | +2.3 | (9.0) |
| \% of net sales | 12.2 | 12.6 | 11.5 |  |  |  |
| SG\&A expenses | 3,396 | 3,870 | 3,840 | +444 | +13.1 | (0.8) |
| \% of net sales | 5.1 | 5.3 | 5.3 |  |  |  |
| Operating profit | 4,742 | 5,280 | 4,486 | (256) | (5.4) | (15.0) |
| \% of net sales | 7.1 | 7.3 | 6.2 |  |  |  |
| Segment profit | 4,879 | 5,390 | 4,731 | (148) | (3.0) | (12.2) |
| \% of net sales | 7.3 | 7.4 | 6.5 |  |  |  |
| Number of pharmacies | 1,074 | 1,211 | 1,210 | +136 | +12.7 | (0.1) |

Figures in the table are rounded down

## Cosmetic and Drug Store Business (Consolidated)

Net sales up $20.2 \%$ YoY and declined $0.7 \%$ against the plan due to the recovery of existing stores and contribution of stores opened in previous year despite the impact of the COVID-19. Segment profit was $¥ 164$ million, $¥ 184$ million above the plan.

|  | $\mathrm{FY} 4 / 221 \mathrm{Q}$ <br> results | $\mathrm{FY} 4 / 231 \mathrm{Q}$ <br> plan | $\mathrm{FY} 4 / 231 \mathrm{Q}$ <br> results | YoY <br> change | YoY <br> change(\%) | Vs plan <br> $(\%)$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 5,063 | 6,130 | 6,086 | $+1,023$ | +20.2 | $(0.7)$ |
| Gross profit | 1,701 | 2,256 | 2,245 | +544 | +32.0 | $(0.5)$ |
| \% of net sales | 33.6 | 36.8 | 36.9 |  |  |  |
| SG\&A expenses | 2,213 | 2,276 | 2,098 | $(115)$ | $(5.2)$ | $(7.8)$ |
| \% of net sales | 43.7 | 37.1 | 34.5 |  |  |  |
| Operating profit <br> \% of net sales | $(511)$ | $(20)$ | 146 | +657 | - | - |
| Segment profit <br> \% of net sales | $(503)$ | $(20)$ | 164 | +667 | - | - |
| Number of <br> stores | - | - | 2.7 |  |  |  |

Figures in the table are rounded down

## Consolidated B/S

Net cash became $¥ 30,947$ million and shareholders' equity ratio became $52.0 \%$. We are maintaining a sound financial structure even during the COVID-19 outbreak.

| End-FY4/22 |  |  | ( $¥$ million) | End-FY4/23 1Q |  |  | ( $¥$ million) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Asse |  | Liabilit |  | Asset |  | Liabilit |  |
| Current assets <br> Cash on hand and in banks | $\begin{array}{r} 100,765 \\ 59,729 \end{array}$ | Current liabilities Short-term debt | $\begin{array}{r} 81,805 \\ 2,643 \end{array}$ | Current assets <br> Cash on hand and in banks | $\begin{array}{r} 96,163 \\ 46,863 \end{array}$ | Current liabilities Short-term debt | $\begin{array}{r} 91,402 \\ 4,167 \end{array}$ |
| Fixed assets <br> Goodwill | $\begin{array}{r} 111,696 \\ 36,352 \end{array}$ | Long-term liabilities Long-term debt | $\begin{array}{r} 11,645 \\ 5,815 \end{array}$ | Fixed assets <br> Goodwill | $\begin{array}{r} 132,231 \\ 49,344 \end{array}$ | Long-term liabilities Long-term debt | $\begin{array}{r} 18,217 \\ 11,218 \end{array}$ |
| Deferred assets | - | Total net assets | 119,010 | Deferred assets |  | Total net assets | 118,773 |
| Total assets | 212,461 | Total liabilities and net assets | 212,461 | Total assets | 228,394 | Total liabilities and net assets | 228,394 |
| Net cash |  |  | 51,030 | Net cash |  |  | 30,947 |
| Shareholders' equity ratio(\%) |  |  | 56.0 | Shareholders' equity ratio(\%) |  |  | 52.0 |

Figures in the table are rounded down
Net cash = Cash on hand and in banks - Interest-bearing debt

## Assets

The balance of total assets increased $¥ 15,933$ million from the end of the previous fiscal year due to decrease of cash on hand and in banks and increase of inventories and goodwill.

| ( $¥$ million) | End-FY4/22 1 Q | End-FY4/22 | End-FY4/23 1Q | Change |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Cash on hand and in banks | 53,576 | 59,729 | 46,863 | $(12,866)$ |
| Notes and accounts receivable | 12,338 | 10,110 | 12,697 | $+2,587$ |
| Inventories | 15,180 | 14,790 | 19,504 | $+4,714$ |
| Total current assets | $\mathbf{9 4 , 8 2 9}$ | $\mathbf{1 0 0 , 7 6 5}$ | $\mathbf{9 6 , 1 6 3}$ | $\mathbf{( 4 , 6 0 2 )}$ |
| Buildings and structures,net | 16,345 | 17,512 | 19,505 | $+1,993$ |
| Land | 9,976 | 8,581 | 10,637 | $+2,056$ |
| Total property, plant and equipment | $\mathbf{3 0 , 1 1 7}$ | $\mathbf{3 0 , 6 3 6}$ | $\mathbf{3 5 , 7 5 5}$ | $\mathbf{+ 5 , 1 1 9}$ |
| Goodwill | 39,079 | 36,352 | 49,344 | $\mathbf{+ 1 2 , 9 9 2}$ |
| Total intangible fixed assets | $\mathbf{4 2 , 7 8 8}$ | $\mathbf{4 1 , 2 1 9}$ | $\mathbf{5 4 , 4 7 9}$ | $\mathbf{+ 1 3 , 2 6 0}$ |
| Investments in securities | 2,638 | 2,503 | 2,649 | +146 |
| Deferred tax assets | 4,633 | 5,319 | 5,957 | +638 |
| Deposits and guarantees | $\mathbf{2 1 , 3 1 3}$ | 22,785 | 23,234 | $\mathbf{+ 4 4 9}$ |
| Total investments and other assets | $\mathbf{3 5 , 8 1 7}$ | $\mathbf{3 9 , 8 4 0}$ | $\mathbf{4 1 , 9 9 6}$ | $\mathbf{+ 2 , 1 5 6}$ |
| Total fixed assets | $\mathbf{1 0 8 , 7 2 2}$ | $\mathbf{1 1 1 , 6 9 6}$ | $\mathbf{1 3 2 , 2 3 1}$ | $\mathbf{+ 2 0 , 5 3 5}$ |
| Total deferred assets | $\mathbf{-}$ | $\mathbf{-}$ | $\mathbf{-}$ | $\mathbf{-}$ |
| Total assets | $\mathbf{2 0 3 , 5 5 2}$ | $\mathbf{2 1 2 , 4 6 1}$ | $\mathbf{2 2 8 , 3 9 4}$ | $\mathbf{+ 1 5 , 9 3 3}$ |

Figures in the table are rounded down $>$ Change:End-FY4/23 1Q compared with End-FY4/22
Capital expenditures (Property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled $¥ 3,210$ million

## Liabilities and Net Assets

Accounts payable increased $¥ 8,706$ million due to new store openings and M\&A. Short-term and long-term debt increased $¥ 6,927$ million.

| ( $¥$ million) | End-FY4/22 1Q | End-FY4/22 | End-FY4/23 1Q | Change |
| :--- | ---: | ---: | ---: | ---: |
| Accounts payable | 49,094 | 50,756 | 59,462 | $+8,706$ |
| Short-term debt | 3,354 | 2,643 | 4,167 | $+1,524$ |
| Total current liabilities | $\mathbf{7 6 , 8 1 6}$ | $\mathbf{8 1 , 8 0 5}$ | $\mathbf{9 1 , 4 0 2}$ | $\mathbf{+ 9 , 5 9 7}$ |
| Long-term debt | 7,507 | 5,815 | 11,218 | $+5,403$ |
| Total long-term liabilities | $\mathbf{1 2 , 9 6 2}$ | $\mathbf{1 1 , 6 4 5}$ | $\mathbf{1 8 , 2 1 7}$ | $\mathbf{+ 6 , 5 7 2}$ |
| Total liabilities | $\mathbf{8 9 , 7 7 8}$ | $\mathbf{9 3 , 4 5 0}$ | $\mathbf{1 0 9 , 6 2 0}$ | $\mathbf{+ 1 6 , 1 7 0}$ |
| Common stock | 21,894 | 21,894 | 21,894 | - |
| Capital surplus | 20,500 | 20,500 | 20,500 | - |
| Retained earnings | 72,878 | 78,661 | 78,433 | $(228)$ |
| Total shareholders' equity | $\mathbf{1 1 3 , 8 7 0}$ | $\mathbf{1 1 9 , 0 3 8}$ | $\mathbf{1 1 8 , 8 1 1}$ | $\mathbf{( 2 2 7 )}$ |
| Total net assets | $\mathbf{1 1 3 , 7 7 3}$ | $\mathbf{1 1 9 , 0 1 0}$ | $\mathbf{1 1 8 , 7 7 3}$ | $\mathbf{( 2 3 7 )}$ |
| Total liabilities and net | $\mathbf{2 0 3 , 5 5 2}$ | $\mathbf{2 1 2 , 4 6 1}$ | $\mathbf{2 2 8 , 3 9 4}$ | $\mathbf{+ 1 5 , 9 3 3}$ |

Figures in the table are rounded down

## FY4/23 Plan (Consolidated)

The group forecasts net sales for the fiscal year ending April 30, 2023 of $¥ 363,000$ million, increase $14.8 \%$ YoY and ordinary profit of $¥ 20,500$ million, increase $27.8 \%$ YoY.

| ( $¥$ million) | FY4/21 results | FY4/22 results | $\begin{gathered} \mathrm{FY} 4 / 23 \\ \text { plan } \end{gathered}$ | YoY change | $\begin{gathered} \text { YoY } \\ \text { change(\%) } \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 297,305 | 316,247 | 363,000 | +46,753 | +14.8 |
| Gross profit | 46,155 | 49,971 | 58,720 | +8,749 | +17.5 |
| \% of net sales | 15.5 | 15.8 | 16.2 |  |  |
| SG\&A expenses | 35,222 | 34,832 | 38,720 | +3,888 | +11.2 |
| \% of net sales | 11.8 | 11.0 | 10.7 |  |  |
| Operating profit | 10,932 | 15,139 | 20,000 | +4,861 | +32.1 |
| \% of net sales | 3.7 | 4.8 | 5.5 |  |  |
| Ordinary profit | 12,649 | 16,041 | 20,500 | +4,459 | $+27.8$ |
| \% of net sales | 4.3 | 5.1 | 5.6 |  |  |
| Profit attributable to owners of parent | 6,697 | 7,092 | 11,000 | +3,908 | +55.1 |
| \% of net sales | 2.3 | 2.2 | 3.0 |  |  |
| Earnings per share( $¥$ ) | 189.04 | 201.47 | 313.15 | +111.68 | +55.4 |
| Annual dividend ( $¥$ ) | 55.00 | 55.00 | 60.00 | +5.00 | +9.1 |

Figures in the table are rounded down

## Review

## Daily new COVID-19 cases across Japan

As of September 1, the number of domestic cases of the COVID-19 infection and deaths was 19,116,887 and 40,245, respectively.

the Ministry of Health, Labour and Welfare's Open Data on the COVID-19
The period of declaration of the state of emergency is taken from the region with the longest period

## Review (YoY)

Ordinary profit increased $¥ 0.2$ billion due to increase of net sales in both dispensing pharmacy and cosmetic and drug store businesses.

```
Net sales +¥6.4 billion
```

Ordinary profit $\mathbf{+} \mathbf{¥ 0 . 2}$ billion

| ¥81.4 billion +8.6\% |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| ¥75.0 billion |  |  | ¥2.8 billion | $¥ 3.0$ billion | +7.9\% |
|  | Dispensing Pharmacy | Dispensing Pharmacy +¥5.6 billion | Dispensing Pharmacy | Dispensing Pharmacy | ■ Dispensing Pharmacy |
| Dispensing |  |  |  |  | Gross profit $¥(0.1)$ billion |
| Pharmacy <br> $\neq 66.8$ billion | $¥ 72.4$ billion | Cosmetic and <br> Drug store $+¥ 1.0$ billion | $¥ 4.8$ billion Others $¥ 0.0$ billio | $¥ 4.7$ billion <br> Cosmetic and Dr Store $¥(0,1)$ bill | Cosmetic and Drug store Cost reform $+¥ 0.6$ billion |
| Cosmetic and Drug | Cosmetic and Drug | $\square$ Retail shop, Others $¥(0,2)$ billion | Cosmetic and Drug Store $¥(0.5)$ billion Administrative expense | Admers $¥ 0.0$ billiol expense $\neq(1.8)$ billion | Administrative expense, |
| Store $¥ 5.1$ billion Others $¥ 3.1$ billion | Store $¥ 6.1$ billion Others $¥ 2.9$ billion | $¥(0.2)$ billion | $¥(1.5)$ billion |  | Others |
| FY4/22 | FY4/23 |  | FY4/22 | FY4/23 |  |
| 1Q | 1Q |  | 1Q | 1Q |  |

## Strategy

## Strategy

## Expansion of top-line and increase profits

$■$ Dispensing Pharmacy Plan to open 160 pharmacies (Organic 48, M\&A 112)
■ Cosmetic and Drug Store Plan to open 10 stores

Recruiting and training of human resources
■ Planning to hire 600 newly graduated pharmacists (hired 660 new pharmacists in FY4/22)
■ Make the Field Manager system more established
$\square$ Training of human resources

## Reinforcing the Group's business base

$\square$ Improving the customer services by promoting DX, such as official apps
■ Promoting Sustainability Management

Turnaround and expansion of AINZ\&TULPE
$■$ Opening stores in prime locations and optimizing costs

## Expansion of top-line and increase profits 1



## Expansion of top-line and increase profits 2

- Plan

| FY4/23 1Q |  |
| ---: | ---: |
| Plan | Results |
| 116 | 117 |
| 8 | 8 |
| 108 | 109 |
| 2 | 2 |
| $\mathbf{1 1 8}$ | $\mathbf{1 1 9}$ |
| 4 | 6 |
| 2 | 1 |
| 6 | $\mathbf{7}$ |
| 1,211 | 1,210 |
| 78 | 79 |
| $\mathbf{1 , 2 8 9}$ | $\mathbf{1 , 2 8 9}$ |


| FY4/23 |
| :---: |
| Plan |
| 160 |
| 48 |
| 112 |
| 10 |
| $\mathbf{1 7 0}$ |
| 10 |
| 5 |
| $\mathbf{1 5}$ |
| 1,249 |
| $\mathbf{8 3}$ |
| $\mathbf{1 , 3 3 2}$ |

- Transition of dispensing pharmacies

|  | $F Y 4 / 17$ | $F Y 4 / 18$ | $F Y 4 / 19$ | $F Y 4 / 20$ | $F Y 4 / 21$ | $F Y 4 / 22$ | $F Y 4 / 231 Q$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Organic | 27 | 25 | 23 | 14 | 15 | 25 | 8 |
| M\&A | 182 | 11 | 134 | 6 | 14 | 24 | 109 |
| $\quad$ EV/EBITDA ratio | 5.50 | 3.96 | 4.88 | 3.71 | 3.74 | 4.13 | 6.87 |
| Closed | 24 | 73 | 54 | 64 | 52 | 15 | 6 |
| $\quad$ Sold | 2 | 32 | 30 | 42 | 34 | 5 | 1 |
| No. of total stores | 1,066 | 1,029 | 1,132 | 1,088 | 1,065 | 1,099 | 1,210 |

[^0]
## Recruiting and training of human resources

In April 2022, new 660 pharmacists has joined our group. We aim to hire roughly the same number in fiscal 2023. As of July 31,2022, the group has 6,154 pharmacists out of 13,774 employees.


## AINZ \& TULPE

AINZ \& TULPE plan to open in FY4/23


MOSAICMALL Kohoku (Opened in May 2022)


KOBE MOTOMACHI (Opened in June 2022)
(Plan to open in
October 2022)


Tokyo
(Plan to open in March 2023)

## FY4/23 Plan (Consolidated)

The group forecasts net sales for the fiscal year ending April 30, 2023 of $¥ 363,000$ million, increase $14.8 \%$ YoY and ordinary profit of $¥ 20,500$ million, increase $27.8 \%$ YoY.

| ( $¥$ million) | FY4/21 results | FY4/22 results | $\begin{gathered} \text { FY4/23 } \\ \text { plan } \end{gathered}$ | YoY change | YoY change(\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 297,305 | 316,247 | 363,000 | +46,753 | +14.8 |
| Gross profit | 46,155 | 49,971 | 58,720 | +8,749 | +17.5 |
| \% of net sales | 15.5 | 15.8 | 16.2 |  |  |
| SG\&A expenses | 35,222 | 34,832 | 38,720 | +3,888 | +11.2 |
| \% of net sales | 11.8 | 11.0 | 10.7 |  |  |
| Operating profit | 10,932 | 15,139 | 20,000 | +4,861 | +32.1 |
| \% of net sales | 3.7 | 4.8 | 5.5 |  |  |
| Ordinary profit | 12,649 | 16,041 | 20,500 | +4,459 | +27.8 |
| \% of net sales | 4.3 | 5.1 | 5.6 |  |  |
| Profit attributable to owners of parent | 6,697 | 7,092 | 11,000 | +3,908 | +55.1 |
| \% of net sales | 2.3 | 2.2 | 3.0 |  |  |
| Earnings per share( $¥$ ) | 189.04 | 201.47 | 313.15 | +111.68 | +55.4 |
| Annual dividend ( $¥$ ) | 55.00 | 55.00 | 60.00 | +5.00 | +9.1 |

Figures in the table are rounded down

## Inquiries related to this presentation should be addressed to

## AIN HOLDINGS INC. Corporate Planning Division TEL(81)11-814-0010 FAX(81)11-814-5550 https://www.ainj.co.jp/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.



[^0]:    $>E V / E B I T D A$ ratio $=E V($ Purchase price)/EBITDA(Operating income + Depreciation and amortization)

